Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 26, Art. 13 (pp. 346-365)    |    2025       

»

Redox status regulation is the biochemical basis for the development of low-dosage medicines

Antonov V.G.1, Каshuro V.А. 1,2,3
1St. Petersburg State Pediatric Medical University, St. Petersburg, Russia
2Herzen State Pedagogical University of Russia, St. Petersburg, Russia
3Saint Petersburg State University, St. Petersburg, Russia

Brief summary

The significant pharmacological activity of a drug's active ingredient is not always consistent with its safety for medical use. Adverse drug reactions are common and costly for the healthcare system. In this regard, the ability to ensure the main effect of a drug without undesirable side effects is no less important than the creation of the active ingredient itself. The paper provides a rationale for using a pharmacological activity potentializer (PAP) in pharmacological solutions that acts through the redox control system of physiological reactions. The pharmacological activity potentiator that provides physiologically adequate redox effects as part of specific therapy can restore the functioning of receptors, eliminate typical disorders of cell interactions, allow the body's own homeostasis normalization systems to eliminate disorders, and use minimal therapeutically sufficient doses of medications and optimal treatment courses. The pharmacological effect of PAP and its pharmaceutical compatibility make it possible to create safe, patent-protected, next-generation combined drugs based on both well-known pharmaceuticals and newly developed drugs that are widely used in clinical practice. PAP promotes the pharmacological activity of biologically active chemical molecules in physiologically optimal doses.


Key words

redox status, pharmacological activity potentializer, glutathione, information and transport system

Reference list

1. Martinovich G.G., Cherenkevich S.N. Okislitelno-vosstanovitelnie processi v kletkah. Mn.: BGY, 2008.


2. Smirnova G.V., Oktyabrskii O.N. Glytation y bakterii. Biohimiya. 2005; 70 (11):1459-1473.


3. Batocirenova E.G., Kashyro V.A., Minaeva L.V. i dr. Signalnaya fynkciya aktivnih form kisloroda pri intoksikacii tiopentalom natriya. Izvestiya Samarskogo naychnogo centra Rossiiskoi akademii nayk. 2014; 16 (5-4): 1376-1379.


4. Filomeni G., Rotilio G., Ciriolo M.R. Cell signalling and the glutathione redox system. Biochem. Pharmacol. 2002; 64: 1057-1064.


5. Jordan P.A., Gibbins J.M. Extracellular Disulfide Exchange and the Regulation of cellular Function. Antioxidants and Redox signaling. 2006; 8 (3-4): 312-324.


6. Gilbert H.E. Glutathione Centennial Molecular Perspectives and Clinical Implications. San Diego: Acad. Press, 1989.


7. Meister A. Glutathione metabolism and its selective modification. J.Biol.Chem. 1988; 263: 17205-17208.


8. Meyer A.J., Hell R. Glutathione homeostasis and redox-regulation by sulfhydryl groups. Photosynth Res. 2005; 86 (3):435-457.


9. Jeffery C.J. Moonlighting proteins. Trends.Biochem. Sci. 1999; 24: 8-11.


10. Paolicchi A., Dominici S., at al. Glutathione catabolism as a signaling mechanism. Biochem. Pharmacol. 2002; 64: 1027-1035.


11. Meister A., Anderson M.E. Glutathione. Annu.Rev.Biochem.1983; 52: 711-760.


12. Droge W., Schulze-Osthoff K. et al. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 1994; 8: 1131-1138.


13. Dubina M.V., Gomonova V.V., et al. Pathogenesis-based preexposure prophylaxis associated with a low risk of SARS-CoV-2 infection in healthcare workers at a designated COVID-19 hospital: a pilot study. BMC Infectious Diseases. 2021; 21:536.


14. Antyshevich A.E., Byzanov D.V., Antonov V.G. i dr. Ocenka effektivnosti primeneniya inozina glicil-cisteinil-glytamata dinatriya pri ostrih tyajelih otravleniyah etanolom. Vestnik Rossiiskoi voenno-medicinskoi akademii. 2017; 58(2): 7-12.


15. Kvetnoi I.M., Mironova E.S., Krilova U.S., i dr. Belki mitohondrii kardiomiocitov kak molekylyarnie misheni targetnogo deistviya preparata V007. Molekylyarnaya medicina. 2021; 19 (6): 31-36.


16. Myzyrov K.V., Antyshevich A.E., Antonov V.G. i dr. Effektivnost primeneniya moliksana pri ostrih tyajelih otravleniyah korvalolom. Skoraya medicinskaya pomosh. 2017; 18(2): 73-77.


17. Kashyro V.A. Patogeneticheskoe i diagnosticheskoe znachenie sistemi glytationa v ocenke citotoksicheskogo deistviya protivoopyholevih preparatov: Avtoref. dis. ... d-ra med. nayk. SPb.; 2009.


18. Droge W., Hack V., Breitkreutz R., et al. Role of cysteine and glutathione in signal transduction, immunopathology and cachexia. Bio Factors. 1998; 8: 97-102.


19. Orlov U.V., Halimov U.Sh., Kyzmich V.G. i dr. Ocenka effektivnosti disylfida glytationa v profilaktike razvitiya fibroza pecheni pri toksicheskom gepatite. Medline.ru. Rossiiskii biomedicinskii jyrnal. 2022; 23(1): 191-118.


20. Mironova E.S., Morozkina S., Snetkov P., et al. Glutathione Medicines as Geroprotectors: Molecular Effects in Inflammaging Model. American Journal of biomedical science and research. 2024; 23(3):577-579.


21. Shikalova I.A., Lodyagin A.N., Antonov V.G, i dr. Rezyltati mnogocentrovogo issledovaniya: effektivnost i bezopasnost preparata inozina glicil-cisteinil-glytamat dinatriya v terapii ostrih otravlenii etanolom. Jyrnal im. N.V. Sklifosovskogo «Neotlojnaya medicinskaya pomosh». 2022;11(3):444-456.

Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций

(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции